OCUL logo

OCUL
Ocular Therapeutix Inc

12,056
Mkt Cap
$1.91B
Volume
3.12M
52W High
$16.44
52W Low
$6.23
PE Ratio
-6.11
OCUL Fundamentals
Price
$8.79
Prev Close
$9.30
Open
$9.31
50D MA
$8.83
Beta
1.46
Avg. Volume
5M
EPS (Annual)
-$1.42
P/B
2.90
Rev/Employee
$159,849.23
$1,613.02
Loading...
Loading...
News
all
press releases
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 7.2% - Time to Sell?
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7.2% - Here's What Happened...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3% - Should You Buy?
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3% - Still a Buy...
MarketBeat·11d ago
News Placeholder
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...
MarketBeat·13d ago
News Placeholder
Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL
Assenagon Asset Management S.A. grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1,261.4% during the fourth quarter, according to its most recent 13F filing with the...
MarketBeat·14d ago
News Placeholder
Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference
Ocular Therapeutix (NASDAQ:OCUL) executives highlighted what the company described as a landmark Phase 3 outcome for its retinal disease candidate AXPAXLI and discussed ongoing development, safety...
MarketBeat·17d ago
News Placeholder
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the stock, MarketBeat...
MarketBeat·18d ago
News Placeholder
Cantor Fitzgerald L. P. Buys Shares of 201,865 Ocular Therapeutix, Inc. $OCUL
Cantor Fitzgerald L. P. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 201,865 shares of the biopharmaceutical company's stock, valued at approximately $2,360,000. Cantor Fi...
MarketBeat·24d ago
News Placeholder
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
Key PointsAdviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value $71.01 million based on quarterly average price...
Nasdaq News: Markets·25d ago
News Placeholder
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 20.0% in February
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·25d ago
News Placeholder
Ocular Therapeutix, Inc. $OCUL Shares Purchased by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC grew its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 38.5% in the 3rd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·29d ago
<
1
2
...
>

Latest OCUL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.